^
    2d
    Pemigatinib-Associated Psoriasis in a Patient With Cholangiocarcinoma. (PubMed, Cureus)
    Recognition and management of dermatologic adverse effects are critical to minimizing morbidity in the setting of life-prolonging oncologic treatments. Given the limitations of a single-case inference, further surveillance and study are needed to determine whether patients with pre-existing psoriasis may be at increased risk.
    Journal
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    Pemazyre (pemigatinib)
    6d
    FGFR2 Fusion Gene-Positive Solid Tumors (PubMed, Gan To Kagaku Ryoho)
    Pemigatinib (approved in 2021) demonstrated a response rate of 35.5%, futibatinib (approved in 2023) showed a response rate of 42%, and tasurgratinib (approved in 2024) achieved a response rate of 30.2%. Polyclonal on-target resistance to pan-FGFR inhibitors and increasing of FGFR2 kinase domain resistance mutations based on treatment history has been reported. Novel therapeutics, such as highly selective FGFR2 inhibitors and next-generation inhibitors, are developed and are expected to improve prognosis for patients with FGFR2 fusion-positive solid tumors.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 mutation • FGFR2 fusion • FGFR fusion
    |
    Lytgobi (futibatinib) • Pemazyre (pemigatinib) • Tasfygo (tasurgratinib)
    9d
    Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial. (PubMed, J Clin Oncol)
    This was the largest, first-line, randomized, phase 3 trial of a targeted therapy for advanced FGFR2-rearranged cholangiocarcinoma. Pemigatinib demonstrated prolonged median PFS compared with chemotherapy, with no new safety findings.
    P3 data • Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 rearrangement
    |
    cisplatin • gemcitabine • Pemazyre (pemigatinib)
    14d
    Improving public cancer care by implementing precision medicine in Norway (2023-507894-16-00)
    P1/2, N=1000, Recruiting, Oslo University Hospital HF | N=6000 --> 1000
    Enrollment change
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • Rozlytrek (entrectinib) • imatinib • Alecensa (alectinib) • Cotellic (cobimetinib) • bortezomib • Piqray (alpelisib) • Zejula (niraparib) • Retevmo (selpercatinib) • Zykadia (ceritinib) • fulvestrant • Jemperli (dostarlimab-gxly) • Pemazyre (pemigatinib) • Tepmetko (tepotinib) • Tabrecta (capmatinib) • dexamethasone • Erivedge (vismodegib) • melphalan • dactinomycin • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • hydroxyurea
    21d
    PA 2506: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (2025-522431-34-00)
    P1/2, N=1200, Not yet recruiting, Region Hovedstaden
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • Mekinist (trametinib) • Xalkori (crizotinib) • erlotinib • Tafinlar (dabrafenib) • Vitrakvi (larotrectinib) • gemcitabine • paclitaxel • 5-fluorouracil • capecitabine • Retevmo (selpercatinib) • albumin-bound paclitaxel • oxaliplatin • irinotecan • Pemazyre (pemigatinib) • axitinib • Erivedge (vismodegib) • leucovorin calcium • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    23d
    FGFR1 but not S6K1/2 drives intrinsic BRAF inhibitor resistance in melanoma. (PubMed, Cell Death Discov)
    Instead, a pooled CRISPR kinome knockout screen uncovered FGFR1 as a key resistance driver, and indeed intrinsic BRAFi resistance was partially to fully reversible in 6 cell lines by the FDA-approved pan-FGFR inhibitor pemigatinib. Overall, our results suggest that although changes in pS6 are an excellent marker of intrinsic BRAFi resistance, the S6K1/2-S6 axis itself is not primarily responsible, and instead that FGFR1 is worth further translational study in the context of intrinsic BRAFi resistance.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1)
    |
    Pemazyre (pemigatinib)
    1m
    A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations. (PubMed, Cancer Res Treat)
    Pemigatinib plus paclitaxel demonstrated antitumor activity with an acceptable safety profile in FGFR2-amplified gastric cancer. Further investigation is warranted to elucidate resistance mechanisms and validate these findings in larger cohorts.
    P1/2 data • Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 fusion
    |
    paclitaxel • Pemazyre (pemigatinib)
    1m
    Real-world patient characteristics and utilization patterns in patients with cholangiocarcinoma who received pemigatinib in the United States of America. (PubMed, ESMO Real World Data Digit Oncol)
    The most common baseline regimen was gemcitabine + cisplatin (34.4%). Treatment patterns, adherence, OS, HCRU, and costs demonstrated consistent trends across racial subgroups. Real-world pemigatinib treatment patterns and survival outcomes were consistent with findings from clinical trials and support continued use of pemigatinib across diverse patient groups as a key second-line treatment for CCA.
    Journal • Real-world evidence
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 fusion
    |
    cisplatin • gemcitabine • Pemazyre (pemigatinib)
    2ms
    PEMIGIST: PH 2 Pemigatinib in SDH-deficient GIST (clinicaltrials.gov)
    P2, N=24, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Pemazyre (pemigatinib)
    2ms
    N6-methyladenosine-mediated up-regulation of ARRB2 regulates intrahepatic cholangiocarcinoma malignant progression and pemigatinib resistance through MAPK and Hippo signaling pathways. (PubMed, Cell Death Dis)
    Functional analyses demonstrated that ARRB2 promotes the malignant progression of ICC by facilitating YAP nuclear translocation while also modulating the sensitivity of ICC to pemigatinib through the Raf-MEK-ERK signaling axis. This study identifies the tumor-promoting activities of ARRB2 and elucidates the regulatory mechanism of the METTL3-ARRB2-YAP/Raf axis in ICC, which may provide a novel prognostic biomarker and potential therapeutic target for human ICC.
    Journal
    |
    ARRB1 (Arrestin Beta 1) • METTL3 (Methyltransferase Like 3)
    |
    Pemazyre (pemigatinib)
    3ms
    Management of Nail Toxicities From Fibroblast Growth Factor Receptor Inhibitors. (PubMed, J Drugs Dermatol)
    The incidence of FGFRi-associated nail toxicities varies by agent and can affect quality of life and treatment adherence. The pathogenesis remains unclear, and no predictive biomarkers exist. Further research into optimized management and preventative strategies is needed. Early recognition and proactive multidisciplinary management are essential to minimizing complications and maintaining oncologic treatment continuity. &nbsp.
    Journal
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    Balversa (erdafitinib) • Lytgobi (futibatinib) • Pemazyre (pemigatinib) • derazantinib (ARQ 087)
    3ms
    Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib. (PubMed, Blood)
    Outside allogeneic stem cell transplantation (ASCT), survival with conventional therapy is dismal, representing an unmet clinical need. We summarize here the data that led to approval of pemigatinib, a FGFR1 inhibitor, showing unprecedented efficacy in M/LN-FGFR1.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1)
    |
    Pemazyre (pemigatinib)